In Vivo Damage Induced bu UV in the Epidermis of the Scalp
Clinical Study of In Vivo Damage Induced bu UV in the Epidermis of the Scalp
1 other identifier
interventional
10
1 country
1
Brief Summary
Squamous cell carcinomas (SCC) are the second most common skin cancer in humans. The incidence of SCCs in the USA in 2012 was estimated at 700,000 casesSCCs have a metastatic course in 3% to 5% of cases that is of poor prognosis. In men, the SCCs of the scalp represent the most frequent location of the head and neck, the 3rd location of the whole body. The SCCs of the scalp are more undifferentiated than in other locations. In addition, actinic keratoses of scalp, precursors of SCC, are more resistant to treatment than in other areas. These particularities of the SCCs of the scalp suggest the existence of specific factors at the epidermis level of the scalp. UV-induced damage to DNA is the defining event in skin photocarcinogenesis. It has already been shown that DNA damage induced by UV and the kinetics of repair of this damage may vary with age or phototype of patients, but the topographic variation of DNA damage has never been studied, although it is known that gene expression in skin cells may differ from one region of the body to another. the hypothesis is therefore that the particular characteristics of KAs and SCCs at the scal level could be explained by an increased sensitivity to UV-induced damage. It is planned to study UV-induced damage and its repair at the scalp level in humans compared to the forearm.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 25, 2019
CompletedFirst Posted
Study publicly available on registry
October 29, 2019
CompletedStudy Start
First participant enrolled
February 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2021
CompletedMay 6, 2022
May 1, 2022
3 months
October 25, 2019
May 5, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
number oh epidermal cells positives
epidermal cells with positive immunolabeling for DNA damage markers (CPD, 6.4PP, p53) count.
6 months
Study Arms (1)
UV and biopsy
OTHERMinimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= "6.4 photoproducts", and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure.
Interventions
the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
Eligibility Criteria
You may qualify if:
- Male subject
- Subject aged 40 to 60 years
- Subject of phototype III or IV
- Subject with no skin lesions on the scalp and forearms
- Subject who has not been exposed to the sun for at least 1 month
- Subject affiliated to social security
- Subject who signed the informed consent form
You may not qualify if:
- Subjects with photosensitivity,
- Subject taking photosensitizing drugs
- Subjects with a history of skin cancer
- Subjects with abnormal healing
- Subjects with immunosuppression
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nice Hospital
Nice, 06000, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 25, 2019
First Posted
October 29, 2019
Study Start
February 1, 2021
Primary Completion
May 10, 2021
Study Completion
July 1, 2021
Last Updated
May 6, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share